For immediate-release film-coated tablets, direct compression of escitalopram oxalate is governed primarily by the particle-size distribution of the salt, not by the nominal assay value alone. The oxalate salt contains escitalopram base at a stoichiometric ratio of 0.7828; therefore, a 10 mg base-content tablet requires 12.78 mg of escitalopram oxalate and a 20 mg base-content tablet requires 25.56 mg. This low mass per tablet places the API below 15% w/w in a typical 150 mg core. On rotary tablet presses operating at 40–80 rpm, unmilled API with D90 above 120 µm can produce visual specking and content uniformity variance that exceeds the acceptance value L1 under USP 〈905〉 and Ph. Eur. 2.9.40. A selected particle-size target is D90 below 80 µm with D50 in the range 10–30 µm, confirmed by laser diffraction according to USP 〈429〉 or Ph. Eur. 2.9.31. Before blending, the API is passed through a 0.6 mm oscillating sieve to break loose agglomerates, and residual moisture is measured by Karl Fischer titration under USP 〈921〉 Method Ic; a target of not more than 2.0% water prevents punch filming and hardness drift during compression. The direct-compression matrix is typically built from microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate, with the disintegrant pre-blended at 0.5–2.0% w/w of the final core. Magnesium stearate is limited to 0.5–1.0% w/w and is added in the final 3–5 min of blending to avoid over-lubrication that lowers tensile strength and delays dissolution because hydrophobic shear coats the filler particles. Tablets are compressed to hardness 50–90 N on a B-tooling rotary press with pre-compression force set to 5–10 kN and main compression force validated for the specific batch size. Friability is kept below 0.8% according to USP 〈1216〉 / Ph. Eur. 2.9.7. The film coating is an aqueous Opadry-type dispersion applied in a perforated pan at inlet air temperature 55–70 °C, product bed temperature 38–45 °C, and pan speed 2–6 rpm, with a weight gain of 2–4%. Immediate-release dissolution is evaluated in 0.1 M HCl at 37 ± 0.5 °C using USP Apparatus 2 at 50 rpm under USP 〈711〉 / Ph. Eur. 2.9.3; product-specific acceptance is not less than 80% released at 30 min where justified by the marketing authorization. Residual solvents, elemental impurities, and degradation products are controlled under ICH Q3C, ICH Q3D with USP 〈232〉 / USP 〈233〉, and ICH Q3B(R2).

Where direct compression is borderline during technology transfer, the matrix is used as a risk assessment rather than a simple pass/fail checklist. A change in D90 from 60 µm to 110 µm can shift content uniformity from compliant to non-compliant without altering mean assay; therefore, incoming API particle-size distribution is released against the approved narrow specification, and the tableting process is not adjusted at press to compensate for raw material drift.

What Flow and Segregation Limits Govern Capsule Filling at 60,000 Capsules per Hour?

At filling speeds above 60,000 capsules per hour, high-speed capsule filling of escitalopram oxalate blends exposes the process to two failure modes that direct compression can mask: bellows-induced air entrainment in dosator nozzles and density-driven segregation during hopper discharge. Hard gelatin or HPMC capsules are filled on machines with dosator or tamping-pin technology, such as those operating at 60,000–150,000 capsules per hour. The fill blend must have a Hausner ratio below 1.35, Carr compressibility below 25%, and angle of repose below 40° to maintain weight variation within ±5% for capsules with net contents below 200 mg. Because escitalopram oxalate is present at 5–20 mg base equivalent per capsule, the API mass fraction can fall below 3%; in that regime, API fines tend to migrate toward the bottom of the hopper if the filler particle size exceeds 100 µm. The corrective sequence is to pre-blend the oxalate salt with an equal portion of lactose monohydrate or pregelatinized starch for 10 min in a low-shear diffusion mixer, then to add the remaining filler and disintegrant and mix for an additional 20–30 min. Lubricant is added at 0.5–0.75% w/w for the final 5 min. Roller-compacted granules may replace powder blends when dusting or segregation persists; ribbon density is controlled at 1.1–1.4 g/cm³ and milled through a 1.0 mm screen. Capsule fill weight is checked by in-process control at intervals not exceeding 30 min using an electronic balance connected to feedback control. Moisture interchange between the capsule shell and the fill is a stability concern: gelatin shells at equilibrium moisture 13–16% w/w can transfer water to the oxalate salt, whereas HPMC shells at 2–6% w/w reduce that flux. Filled capsules are tested for disintegration under USP 〈701〉 / Ph. Eur. 2.9.1, content uniformity under USP 〈905〉 / Ph. Eur. 2.9.40, and dissolution under USP 〈711〉. If the dissolution curve is sensitive to magnesium stearate level, the formulation is reworked by reducing lubricant concentration to 0.5% or by using sodium stearyl fumarate at 0.5–1.5% w/w. Packaging in PVC/PVDC/aluminum blisters with desiccant is appropriate where the 18-month stability protocol at 25 °C / 60% RH and 40 °C / 75% RH shows moisture-induced degradation; the storage condition follows ICH Q1A(R2).

In capsule filling, the apparent density of the oxalate salt itself is a critical incoming-material attribute because a lot-to-lot density shift above 0.2 g/cm³ can change the dosator chamber fill even when the machine settings remain identical. On dosator machines, the pin height is set to compress the powder column, and a low-density lot can result in underfilled capsules below the control limit. For this reason, incoming API bulk density and tapped density are measured under USP 〈616〉 Method I or Ph. Eur. 2.9.34, and the Hausner ratio is trended across batches. If the Hausner ratio exceeds 1.35, the route is switched to roller compaction before encapsulation.

Oral Solution and Drop Formulation: pH, Preservative, and Light-Exposure Constraints

In liquid oral dosage forms, pH control below the pKa of the free base is required to maintain solubility and to suppress reversion to insoluble escitalopram base. The free base has an estimated pKa of 9.5; at pH 4.0–5.0, the population of ionized species exceeds 99%, allowing a 1 mg/mL base-equivalent solution to be prepared from 1.28 mg/mL escitalopram oxalate under the salt/base factor 0.7828. A citrate buffer at 10–50 mM is often used because it provides buffer capacity without the calcium precipitation risk associated with phosphate buffers; however, the buffer molarity must not exceed the preservative’s minimum effective concentration due to partitioning effects. Sodium benzoate at 0.1% w/v or methylparaben and propylparaben at combined concentrations allowed by the target market are added as antimicrobial preservation, and the final formulation is tested by the antimicrobial effectiveness test under USP 〈51〉 or Ph. Eur. 5.1.3. The vehicle typically contains sorbitol or glycerin as a non-crystallizing humectant to reduce cap-lock crystallization, and peppermint oil or another compendial flavor to mask the amine odor of the API. Because escitalopram may degrade under light stress in dilute aqueous solution, the product is filled into amber Type III glass bottles with child-resistant closures and a low-density polyethylene insert; the container-closure system is qualified under ICH Q1B and USP 〈1664〉 for leachables. Deliverable volume is checked according to USP 〈698〉 or Ph. Eur. 2.9.17, and the dosing device is calibrated to deliver a single 5 mg dose in 5 mL or a drop-equivalent dose.

During commercial manufacturing, the oxalate salt is dissolved in a jacketed stainless-steel vessel at 20–30 °C with propeller agitation at 150–300 rpm; nitrogen overlay may be applied if dissolved oxygen exceeds 2 mg/L. Filtration through a 0.45 µm membrane before filling removes undissolved particulates, and the filled bottles are subjected to in-process torque testing and visual inspection. Stability-indicating HPLC under ICH Q2(R1) is used to track the main degradation product, the corresponding N-demethylated compound, so that the shelf-life specification is set from real-time and accelerated storage data. If the solution is packaged as a multi-dose container, the preservative assay is monitored at release and at stability time points; loss of preservative below 90% of the label claim triggers a recall risk assessment and is not accepted without a supporting preservative efficacy test.

When direct compression is not manufacturable at commercial scale, granulation routes for escitalopram oxalate are introduced for low-dose sachet products or orally disintegrating tablet intermediates where the API must be embedded in a rapidly dispersing matrix. Dry granulation by roller compaction is preferred over aqueous wet granulation because prolonged contact with water can hydrate the oxalate salt and shift the final blend moisture above the compression window. A roller compactor with smooth or knurled rolls is operated at hydraulic pressure 20–60 kN/cm, roll speed 2–10 rpm, and gap 2–4 mm, producing ribbons with density 1.1–1.4 g/cm³. Ribbons are milled through a 1.0 mm screen with an oscillating granulator at 50–100 rpm; the resulting granules are classified by sieve analysis under USP 〈786〉, and the fraction between 125 µm and 500 µm is retained for compression. For orally disintegrating tablets, mannitol, microcrystalline cellulose, crospovidone, and a flavoring agent are blended with the milled granules; crospovidone is used at 2–5% w/w because it creates pore networks without gelling. Tablet hardness is deliberately reduced to 20–40 N to keep in vivo disintegration below 60 s when tested by USP 〈701〉; this lower hardness mandates friability not more than 1.0% under USP 〈1216〉 and careful selection of a low-wear tooling configuration. If a sachet or suspension granule is required, the granulate is packaged with a desiccant and the final moisture content is controlled at ≤2.0% by loss on drying under USP 〈731〉. Blend uniformity of the granulated intermediate is assessed by stratified sampling at 10 locations across the blender, with acceptance values following USP 〈905〉 or Ph. Eur. 2.9.40. Dissolution of the granules is tested in 0.1 M HCl using Apparatus 2 at 50 rpm, and the release profile is compared with the reference tablet under similarity factor f2 calculation.

Because the granulation approach changes surface area and compact density, an increase in dissolution lag time may occur if the granule hardness exceeds 2–3 kp; this is corrected by reducing roll pressure or by adding croscarmellose sodium at 1–3% w/w intragranularly. For orodispersible tablets, the final tablet must disintegrate in the oral cavity without water; the in-process control therefore includes a wetting time test in a 10 mL Petri dish at 37 °C with a target of ≤30 s when tested on a textured tongue-simulating surface. Published data for this specific configuration is limited; each formulation is therefore developed under a site-specific design-of-experiments matrix that includes roll pressure, screen size, and superdisintegrant level as variables.

When Injectable Use Is Evaluated: Sterility Assurance and Regulatory Boundary

Outside the approved labelling in most jurisdictions, parenteral application of escitalopram oxalate sits in a restricted regulatory space, and published data for a commercial injectable formulation are limited. Where a hospital pharmacy or clinical investigator prepares a sterile admixture, the oxalate salt is dissolved in Water for Injection at a concentration equivalent to 5 mg/5 mL or 10 mg/10 mL, and the solution is buffered to pH 4.0–5.0 with citrate or acetate. Phosphate buffers are avoided when calcium-containing diluents might be co-administered because free oxalate can precipitate as calcium oxalate; the admixture is therefore labeled incompatible with Ringer’s lactate and Hartmann’s solution. Sterile filtration is carried out through a 0.22 µm PVDF or PES membrane under aseptic conditions in an EU GMP Annex 1 Grade A environment; filter integrity is confirmed by bubble point or diffusion test before and after filtration. Filled vials are tested for particulate matter by light obscuration under USP 〈788〉 Method 1 or Ph. Eur. 2.9.19, and sterility is confirmed by membrane filtration under USP 〈71〉.

Because no pharmacopoeial monograph for escitalopram injection exists, the preparation must be supported by stability-indicating HPLC under ICH Q2(R1) and a bracketing study that covers the intended storage period; chemical stability beyond 24 h at 2–8 °C cannot be assumed without site-specific data. The oxalate counterion also imposes a daily excipient exposure limit; the no-observed-adverse-effect level for oxalate should be reviewed against the intended dose before use. Any injectable use is an unlicensed preparation and falls under local compounding or investigational frameworks, including 21 CFR 210, 21 CFR 211, or national hospital pharmacy regulations. The terminal sterilization of escitalopram oxalate by autoclaving is not recommended without thermal degradation mapping by differential scanning calorimetry and high-performance liquid chromatography, because the molecule may degrade under prolonged heat. Aseptic filtration, rather than terminal sterilization, is therefore the default if a parenteral form is justified by clinical need.